IND Application submitted to the FDA for Ph 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations September 7, 2022
Oxford BioTherapeutics Announces Collaboration with Agenus toSupport the Clinical Development of OBT’s Antibody DrugConjugate OBT076 in combination with Agenus CPI Balstilimab June 14, 2022
FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab June 14, 2022
Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene Fusions June 14, 2022
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500) June 13, 2022
Trethera Phase 1 Solid Tumors Trial Dose Escalates To Fourth Cohort After Safety Review Committee Determines Primary Trial Endpoint Achieved June 13, 2022
FDA Clearance to Proceed with Ph 1b/2 Trial of ADG126 SAFEbody® in Combination with Pembrolizumab Announced March 17, 2022
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates March 5, 2022
First patient dosed with ADG106 + ADG116 combination in Ph 1b/2 trial in solid tumors January 28, 2022
Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked ADC Candidates December 23, 2021
FDA Clears IND for Phase 1b/2 Trial of ADG116 in Combination with Pembrolizumab in Patients with Solid Tumors November 30, 2021
Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance ADG106 in Combination with KEYTRUDA August 20, 2021
Adagene Announces Clinical Trial Collaboration With Merck to Advance ADG116 and ADG126 in Combination with KEYTRUDA July 25, 2021
Interim dose-escalation data up to 0.3 mg/kg in Ph 1 clinical of ADG116 in patients with advanced/metastatic solid tumors announced March 30, 2021
Exelixis and Adagene to Develop Novel Masked ADCs with Improved Safety and Efficacy Profiles February 6, 2021
ARC Therapeutics Launched to Develop CDK Inhibitors for the Treatment of Advanced and Resistant Cancers August 6, 2020
TC BioPharm Partners with Trinity College Dublin to Develop V Delta 1 γδ T Cell-based Cancer Treatments February 26, 2019
